ClinicalTrials.gg
CompletedNCT01794208Updated May 7, 2021

Efficacy and Safety of FSH-GEX™ in Comparison With 150 IU Gonal-f®

A Phase 2 interventional study of Follitropin Epsilon and Follitropin Alfa in Infertility, sponsored by Glycotope GmbH. Completed at 8 sites in 2 countries. Open to female participants aged 18 Years to 37 Years. Per ClinicalTrials.gov, last updated 2021-05-07.

Sponsored by Glycotope GmbH · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
267
Allocation
Randomized
Ages
18 Years to 37 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing Follicle Stimulating Hormone in Infertility — 1 open to participants now, 1 under way, none of them phase 3. Follicle Stimulating Hormone · Infertility.

Enrollment
6th of 12
267 · median 239
Started
2013
with 1 other
Phase 2
Only one
of the 12
Registered
6th of 12
by date
Lead sponsor
1 of 12
Glycotope GmbH

Among the 12 studies testing Follicle Stimulating Hormone in Infertility, this one is the 6th largest by enrollment, is one of 2 that started in 2013, is the only one in phase 2, and was the 6th registered.

Infertility

2,089 studies on the registry are indexed under Infertility; 355 are open to participants now.

Browse Infertility studies →

Open to participants now

1 of the 12 studies testing Follicle Stimulating Hormone in Infertility is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About Follicle Stimulating Hormone

Follicle Stimulating Hormone: first FDA approval 1997 (GONAL-F). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 233 Infertility studies recruiting now, 43 (18%) set no upper age limit and 184 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.

This study: 18 Years to 37 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing Follicle Stimulating Hormone in Infertility, or all of them as a file.
02

Study summary

The aim of the current study was the determination of the recommended standard treatment dose of FSH-GEX(TM) in women undergoing intracytoplasmic sperm injection (ICSI) treatment as assessed by follicle growth.

Read the detailed description

This was a phase II, randomized, assessor-blind, comparator-controlled, multiple dose study in women undergoing ICSI treatment.

The primary objective of the study was the determination of the recommended standard treatment dose of FSH-GEX™ as assessed by follicle growth dynamics in women between 18 and 37 years of age who were undergoing intracytoplasmic sperm injection treatment.

03

Conditions studied

  • Infertility

Browse trials for

Keywords

  • in-vitro fertilization
  • reproductive disorder
04

Who can participate

Ages eligible
18 Years to 37 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female patient for whom ICSI treatment is justified
  • Serum follicle-stimulating hormone concentration
  • Anti-mullerian hormone concentration
  • Antral follicle count
  • and body weight
  • Presence of both ovaries
  • Regular spontaneous cycles between 21 and 35 days in length
  • Normal uterine cavity as assessed by transvaginal sonography at Screening
  • Willing and able to comply with the protocol
  • Willing and able to provide written

Exclusion criteria

Exclusion Criteria:

  • Patients who had more than two unsuccessful previous assisted reproduction technology cycles before inclusion into the study
  • Previous poor responders
  • Patients with previous hyperstimulation syndrome or cycle cancellation because of imminent hyperstimulation syndrome
  • Patients with a history of or current polycystic ovarian morphology syndrome
  • Patients with a history of or current endometriosis III or IV
  • Presence of ovarian cyst at Screening
  • Any to becoming pregnant
  • History of ≥ 3 clinical or preclinical miscarriages
  • Abnormal cervical smear, Papanicolaou [PAP] score ≥ 3
  • Any history of malignant cancer other than in situ breast or skin cancer requiring local excision
  • Any endocrine abnormalities requiring treatment
  • Any systematic disease
  • Any known infection with , or C
  • History of thrombosis or other risk factors including any coagulation abnormality leading to an increased risk of clotting
  • Family history of genetic risk factors concerning pregnancy or birth
  • Use of concomitant medication, which in the opinion of the investigator might interfere with ICSI preparation procedures
  • Active smoking
  • Any active substance abuse of drugs, medications or alcohol within the last five years
  • Patients in an institution by official or court order
  • Patients who are unable or unwilling to provide
  • Any participation in another clinical trial within the last 60 days before randomisation
  • Previous FSH-GEX™ administration.
  • Known to any component of the and non investigational products used in this study
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
267 participants (actual)

Study arms

  • Experimental
    treatment 1

    Follitropin Epsilon 52.5 IU quaque die (QD) s.c.

    Drug: Follitropin Epsilon

  • Experimental
    treatment 2

    Follitropin Epsilon 75 IU QD s.c.

    Drug: Follitropin Epsilon

  • Experimental
    treatment 3

    Follitropin Epsilon 112.5 IU QD s.c.

    Drug: Follitropin Epsilon

  • Experimental
    treatment 4

    Follitropin Epsilon 150 IU QD s.c.

    Drug: Follitropin Epsilon

  • Experimental
    treatment 5

    Follitropin Epsilon 150 IU quaque altera die (QAD) s.c.

    Drug: Follitropin Epsilon

  • Active comparator
    treatment 6

    Follitropin alfa 150 IU QD s.c.

    Drug: Follitropin Alfa

Interventions

06

What researchers measure

Primary outcomes

  1. Number of follicles

    The number of follicles with a diameter of ≥ 12 mm on the day of human chorionic gonadotropin (hCG) injection after stimulation with follicle stimulating hormone (FSH)

    Time frame: day of hCG injection; variable timeframe; up to 18 days for maximum

Secondary outcomes

  1. Follicular response

    For each ovary the number of follicles were classified and summarised as follows: mean diameter 8.0 - 9.9 mm, 10.0 - 11.9 mm, 12.0 - 13.9 mm, 14.0 - 15.9 mm, 16.0 - 17.9 mm, 18.0 - 19.9 mm, and \>19.9 mm as determined by transvaginal ultrasonography

    Time frame: every second day up to hCG injection; variable timeframe; up to 18 days for maximum

  2. Cumulus-oocyte-complexes

    Number of retrieved cumulus-oocyte-complexes

    Time frame: at oocyte retrieval; 32 - 36 hours after hCG injection

  3. Oocytes retrieved

    Number of oocytes retrieved (metaphase II)

    Time frame: at oocyte retrieval; 32 - 36 hours after hCG injection

  4. Two pronuclei oocytes

    Number of two pronuclei (2PN) oocytes one day after follicle puncture

    Time frame: one day after oocyte retrieval

  5. Biochemical pregnancy rate

    Based on positive β-hCG pregnancy test

    Time frame: 14 to 20 days after oocyte retrieval

  6. Clinical pregnancy rate

    Based on clinical or ultrasound parameters (gestational sac, foetal heart beat

    Time frame: approx. 4 to 6 weeks after last FSH dose

  7. Implantation rate

    Number of foetal sacs on sonography divided by number of embryos transferred per embryo transfer

    Time frame: approx. 4 to 6 weeks after last FSH dose

  8. Estradiol and inhibin B serum levels

    Concentration of Estradiol and Inhibin B in Serum after FSH stimulation

    Time frame: every second day up to hCG injection; variable timeframe; up to 18 days maximum

  9. Adverse events, ovarian hyperstimulation syndrome, anti-drug-antibodies, overall tolerability

    Incidence of adverse events, ovarian hyperstimulation syndrome, anti-drug-antibodies, overall tolerability

    Time frame: up to 4 to 6 weeks after last FSH dose

  10. Number of doses and total dose of FSH

    The total dose is the amount of FSH-GEX(TM) or Gonal-f® administered to each patient during the stimulation period

    Time frame: variable timeframe; up to 18 days for maximum

Other outcomes

  1. Ongoing pregnancy rate

    A pregnancy is considered an ongoing pregnancy if pregnancy can be confirmed for more than 10 weeks after gestation.

    Time frame: 10 weeks after gestation

  2. Life birth rate

    The live birth rate will be calculated as the total number of live births divided by the number of randomised patients

    Time frame: up to nine month after embryo transfer

07

Study locations

8 sites
  • Glycotope Investigational Site
    Berlin, 10117, Germany
  • Glycotope Investigational Site
    Berlin, 14050, Germany
  • Glycotope Investigational Medical Director
    Bielefeld, 33619, Germany
  • Glycotope Investigational Site
    Düsseldorf, 40219, Germany
  • Glycotope Investigational Site
    Heidelberg, 69115, Germany
  • Glycotope Investigational Site
    Lübeck, 23538, Germany
  • Glycotope Investigational Site
    Budapest, 1125, Hungary
  • Glycotope Investigational Site
    Tapolca, 8300, Hungary
08

References and documents

Publications

  • Griesinger G, Dietrich B, Stockl L, Eckert K, Goletz S, Tandler-Schneider A. Fully human glyco-optimized recombinant FSH (follitropin epsilon) - a randomized, comparator-controlled phase II clinical trial. Reprod Biomed Online. 2020 Feb;40(2):331-341. doi: 10.1016/j.rbmo.2019.09.003. Epub 2019 Sep 16. PubMed 31982355 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2013 to primary completion in Jul 2013, 6 months.

Of 30 phase 2 interventional studies under Infertility, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 42. This study's 6 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2013
First posted
Feb 18, 2013
StartActual
Jan 8, 2013
Primary completionActual
Jul 2013
CompletionActual
Jul 30, 2013
Last update
May 7, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 7, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01794208
Lead sponsor
Glycotope GmbH
Responsible party
Sponsor
First posted
Feb 18, 2013
Start date
Jan 8, 2013
Primary completion
Jul 2013
Completion
Jul 30, 2013
Last update
May 7, 2021

Study contacts

Study Director
study director · Glycotope GmbH

Oversight

Data monitoring committee
No
FDA-regulated drug
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Follicle Stimulating Hormone

Start the discussion